GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

FDA Offers Clues to How It Will Pave the Way to Getting Biosimilars on the Market

Paper in NEJM divulged the broad strokes of agency’s plans, but nuts and bolts are still up in the air.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?